File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Metabolic dysfunction-associated fatty liver disease (MAFLD) – How relevant is this to Endocrinologists?
Title | Metabolic dysfunction-associated fatty liver disease (MAFLD) – How relevant is this to Endocrinologists? |
---|---|
Authors | |
Issue Date | 2021 |
Citation | 38th Annual Scientific Meeting and Annual General Meeting of the Hong Kong Society of Endocrinology, Metabolism and Reproduction (HKSEMR) 2021: Advances in Diabetes and Metabolism, Hong Kong, 7 November 2021 How to Cite? |
Abstract | Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new entity recently proposed by a
panel of international experts. It is defined as the presence of hepatic steatosis in addition to any one
of the three criteria including overweight or obesity, type 2 diabetes (T2D) and/or clinical evidence of
metabolic dysregulation, such as central obesity, dyslipidaemia and prediabetes. Although there have
been controversies in the field about this change in nomenclature, MAFLD emphasizes the contribution
of metabolic dysfunction as a key driver to adverse outcomes in fatty liver disease. Non-alcoholic
fatty liver disease (NAFLD) in T2D is common and constitutes a significant proportion of patients
with MAFLD. T2D is a major driver to NAFLD progression. The increased awareness of NAFLD as an
emerging major diabetic complication is therefore highly relevant to endocrinologists who often look
after T2D patients especially at their advanced stage. This talk will provide an update in the diagnosis
and management of MAFLD, especially in the context of T2D.
|
Description | Symposium Lecture (III): Clinical |
Persistent Identifier | http://hdl.handle.net/10722/312992 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, CHP | - |
dc.date.accessioned | 2022-05-25T01:58:11Z | - |
dc.date.available | 2022-05-25T01:58:11Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | 38th Annual Scientific Meeting and Annual General Meeting of the Hong Kong Society of Endocrinology, Metabolism and Reproduction (HKSEMR) 2021: Advances in Diabetes and Metabolism, Hong Kong, 7 November 2021 | - |
dc.identifier.uri | http://hdl.handle.net/10722/312992 | - |
dc.description | Symposium Lecture (III): Clinical | - |
dc.description.abstract | Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new entity recently proposed by a panel of international experts. It is defined as the presence of hepatic steatosis in addition to any one of the three criteria including overweight or obesity, type 2 diabetes (T2D) and/or clinical evidence of metabolic dysregulation, such as central obesity, dyslipidaemia and prediabetes. Although there have been controversies in the field about this change in nomenclature, MAFLD emphasizes the contribution of metabolic dysfunction as a key driver to adverse outcomes in fatty liver disease. Non-alcoholic fatty liver disease (NAFLD) in T2D is common and constitutes a significant proportion of patients with MAFLD. T2D is a major driver to NAFLD progression. The increased awareness of NAFLD as an emerging major diabetic complication is therefore highly relevant to endocrinologists who often look after T2D patients especially at their advanced stage. This talk will provide an update in the diagnosis and management of MAFLD, especially in the context of T2D. | - |
dc.language | eng | - |
dc.relation.ispartof | Hong Kong Society of Endocrinology, Metabolism and Reproduction (HKSEMR) 38th Annual Scientific Meeting, 2021 | - |
dc.title | Metabolic dysfunction-associated fatty liver disease (MAFLD) – How relevant is this to Endocrinologists? | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Lee, CHP: pchlee@hku.hk | - |
dc.identifier.authority | Lee, CHP=rp02043 | - |
dc.identifier.hkuros | 331011 | - |
dc.publisher.place | Hong Kong | - |